The price of Moderna shares doubled after the publication of successful trial results for an mRNA-based cancer vaccine, which showed that it helps high-risk melanoma patients prevent cancer recurrence or spread. Both investors and scientists are critically awaiting these results, as they could open doors to a new treatment sector and improve Moderna's financial position. (translated)








